PatientsVille.com LogoPatientsVille.com

Ritonavir News

Ritonavir News

Janssen Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with ...

RARITAN, N.J., April 1, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a once-daily fixed-dose antiretroviral combination tablet containing darunavir, a protease inhibitor developed by Janssen R&D Ireland and marketed as PREZISTA® in the U.S ...

Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir ...

Bristol-Myers Squibb Company announced today the submission of a new drug application on April 4, 2014 to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz®, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make ...

Press Release

ABBVIE INC. Posted on: 24 Mar 14 NORTH CHICAGO Ill. March 24 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress™ (ILC) in London April 9-13.

AbbVie to Present Detailed Results from Phase III Studies in Patients with Chronic Hepatitis C at the 2014 ...

NORTH CHICAGO, Ill., March 24, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress™ (ILC) in London, April 9-13. Detailed results from the SAPPHIRE-I, SAPPHIRE-II, PEARL-III, and...

BMS Files Reyataz-Cobicistat Combo Tablet NDA For HIV-1

Bristol-Myers Squibb announced the filing of a New Drug Application for the fixed-dose combination tablet of atazanavir sulfate (marketed under the brand name Reyataz) with cobicistat for the treatment of patients with HIV-1.

AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients ...

LONDON, April 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that detailed results from its phase III pivotal study, SAPPHIRE-I, will be presented today at the International Liver Congress ™ (ILC) ...

Enanta Pharmaceuticals Announces Detailed Data from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis ...

Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that detailed results from AbbVie’s pivotal phase 3 TURQUOISE-II study, will be presented as a late-breaking oral presentation today at the International Liver Congress , which is the 49th Annual Meeting of the ...

Enanta Pharmaceuticals Announces Detailed Data from SAPPHIRE-I and SAPPHIRE-II Phase 3 Studies in Patients with ...

Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that detailed results from AbbVie’s pivotal phase 3 SAPPHIRE-I study, will be presented today at the International Liver Congress , which is the 49th Annual Meeting of the European Association for the Study of the ...

AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the ...

LONDON, April 12, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced that new, detailed results from its hepatitis C development program will be presented today at the International Liver Congress TM (ILC) ...

Spread the word: Share, Email, Print

Discuss Ritonavir

Did You Have a Ritonavir Side Effect?

Yes, Severe
Yes, Moderate
Yes, Minor
No

How Effective is Ritonavir for You?

Exceeded Expectations
Effective
Somewhat Effective
Not Effective

Record and Track Your Side Effects

It is very important to keep track of all side effects and discuss them with your doctor. If you think you may have a medical emergency, call your doctor or 911 immediately.

Track Your Side Effects - It's Easy and Free. >> Start Today

Already a User? Log In

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Notice - The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. Viewing and using of this information is subject to accepting Terms Of Use. PatientsVille.com does not provide medical advice, diagnosis or treatment. The information regarding adverse reports, reviews and polls contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of side effects, adverse drug reactions or for establishing or changing of patient treatments. Thank you for visiting Patientsville.com!
Privacy | Terms | Contact us